Capecitabine (Cape) is routinely used for the neoadjuvant chemoradiation treatment (NACRT) of locally advanced rectal cancers (LARCs). Previous reports have suggested that the concomitant use of proton pump inhibitors (PPIs) may affect the efficacy of Cape, although the true effect of PPIs when used with Cape as a radiosensitizer for neoadjuvant radiation is unclear. The aim of our study was to evaluate the impact of concurrent PPI use along with fluorouracil (FU) and Cape based NACRT in terms of pathologic and oncological outcomes, in patients with LARC.

中文翻译：

---

质子泵抑制剂与卡培他滨新辅助放化疗联合治疗局部晚期直肠癌：安全吗？

卡培他滨 (Cape) 常规用于局部晚期直肠癌 (LARC) 的新辅助放化疗 (NACRT)。先前的报告表明，质子泵抑制剂（PPIs）的同时使用可能会影响 Cape 的疗效，尽管 PPI 与 Cape 一起用作新辅助放疗的放射增敏剂时的真实效果尚不清楚。我们研究的目的是评估同时使用 PPI 与氟尿嘧啶 (FU) 和基于 Cape 的 NACRT 对 LARC 患者的病理和肿瘤学结果的影响。